TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02447237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary counselling
Description: the participants will receive dietary counselling in fulfilling their need of energy and protein according to the group they are randomized to (either solid or liquid food).

Intervention type: OTHER
Group type: OTHER
Intervention: dietary counselling
Description: the participants will receive dietary counselling in fulfilling their need of energy and protein according to the group they are randomized to (either solid or liquid food).
Study: NCT03278704

Intervention type: OTHER
Group type: OTHER
Intervention: RE only
Description: 8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RE + HIIT
Description: 8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise. Concurrent training: RE followed by HIIT within the same session.
Study: NCT01996839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate Gel (BID)
Description: One drop of LE gel instilled into the study eye two times per day (BID) for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate Gel (TID)
Description: One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle (BID)
Description: One drop of vehicle instilled into the study eye two times per day (BID) for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle (TID)
Description: One drop of vehicle instilled into the study eye three times per day (TID) for 14 days
Study: NCT00228176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rimonabant)
Description: Tablet, oral administration
Study: NCT02575027

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: Undergo 4pi palliative radiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy Treatment Planning and Simulation
Description: Undergo 4pi radiation simulation and planning
Study: NCT00749567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150mg daily, continuously, until disease progression or the appearance of unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression or the appearance of unacceptable toxicity
Study: NCT01620320

Intervention type: OTHER
Intervention: Stress echocardiography
Description: Patients able to exercise will have a treadmill test + echography; the others will have a dobutamine echography.
Study: NCT02123472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Administered Orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Administered Orally
Study: NCT01929499

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cytokine-induced killer cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cytokine-induced killer cells
Study: NCT01672177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic disease self-management training
Description: Those in the intervention group will receive two hour long weekly training sessions for seven-eight months (a total of 56 hours of training).
Study: NCT01762566

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: xylose
Description: placebo (xylose) will be administered blindly versus wheat in a capsule once
Study: NCT01260103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Study subjects in a fasting state receive TMZ orally once a day for five consecutive days (days 1 through 5) at a starting dose of 200 mg/m2/day. Treatment cycles are repeated every 28 days following the first daily dose of TMZ from the previous cycle. In the absence of PD or unacceptable toxicity, subjects continue to receive TMZ for a maximum of 13 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANP Therapy
Description: Escalating doses of ANP therapy are administered for 52 weeks. If the study subject has an OR or maintains SD, ANP therapy is continued.
Study: NCT01414348

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation.
Description: 1 hour / 2x / week for up to 15 sessions
Study: NCT01130987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized handoff tool
Description: Computer program that facilitates accurate transmission of patient information between residents

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team training
Description: Training in teamwork and reorganization of handoff processes to optimize transmission of information and team care
Study: NCT02225548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline
Study: NCT01414348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Novel rehabilitation approach
Description: 1 hr, 2x/week for up to 15 sessions
Study: NCT02149667

Intervention type: DEVICE
Intervention: total hip arthroplasty implant
Study: NCT02225548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Study: NCT03088865

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: aspirating first blood volume into a regular blood collection tube
Description: order of blood drawing

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: aspirating first blood volume into a regular blood collection tube
Description: order of blood drawing
Study: NCT03652142

Intervention type: OTHER
Intervention: Biomarker Research
Description: The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks. Patient samples will be collected with appropriate written informed consent and analyzed.

Intervention type: DRUG
Intervention: Nivolumab
Description: The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks.
Study: NCT03004378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Tracker
Description: Fitbit Alta
Study: NCT00477165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: 20mg/day for 4 weeks, then 40 mg/day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to citalopram 20mg capsules; 1 capsule/day for 4 weeks, then 2 capsules/day for 4 weeks
Study: NCT03343275

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lit control pHDown
Description: Patients within the experimental arm will receive dietary supplement Lit-control®pH Down to help them keep their urinary pH in the adequate levels, being these considered as the preventive ones to avoid stent calcification (pH\<6.2) being the 3 capsule per day indication. On the other hand, the control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics. Both arms wil use Lit-Control® pH Meter device to keep self- control of the urinary pH; also, both will receive the same hygienic-dietary indications about the care of the stent.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Lit control pHDown
Description: Patients within the experimental arm will receive dietary supplement Lit-control®pH Down to help them keep their urinary pH in the adequate levels, being these considered as the preventive ones to avoid stent calcification (pH\<6.2) being the 3 capsule per day indication. On the other hand, the control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics. Both arms wil use Lit-Control® pH Meter device to keep self- control of the urinary pH; also, both will receive the same hygienic-dietary indications about the care of the stent.
Study: NCT03803332

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy
Description: Psychotherapy including imaginal and in vivo exposure for PTSD.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning.
Study: NCT01277094

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral daily doses for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5093151
Description: Oral daily doses for 12 weeks
Study: NCT04506697

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uroflowmetry
Description: The patient is given a portable uroflowmeter for performing uroflowmetry at home, and the NetHealth app is installed on his smartphone. The patient registers his account in the app. A personal uroflowmeter is paired with the patient's smartphone using the installed app via a Bluetooth connection. The investigator trains the patient how to use the app and how to conduct uroflowmetry at home. The patient within 1 day (24 hours) at home performs uroflowmetry during all urination, including night urination.
Study: NCT02377375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-assisted technique
Description: Medtronic DBS lead 3391-28cm Medtronic electrode array microrecording 22670

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique
Description: Medtronic DBS lead 3391-28cm
Study: NCT03123497

Intervention type: OTHER
Intervention: completion of questionnaire
Description: completion of questionnaire for patient and parent
Study: NCT01564927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture to right LI4 and LI11 (ITO, EX-160)
Description: Electroacupuncture at 2Hz, 0.4m/sec pulse duration

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Electroacupuncture to knee caps
Description: Electroacupuncture at 2Hz, 0.4m/sec pulse duration

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham electroacupuncture to LI4 and LI11
Description: Electroacupuncture at 2Hz, 0.4m/sec pulse duration
Study: NCT04002310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754132
Description: One single injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754132
Description: One single injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754132
Description: One single injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754132
Description: One single injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754132
Description: One single injection
Study: NCT04647955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride
Description: Itopride is a D2 antagonist and cholinesterase inhibitor with prokinetic effects on gastric motility used to treat functional dyspepsia. Patients were treated for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were treated for 8 weeks.
Study: NCT02205684

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer game skills training
Description: Playing Nintendo Wii Sports

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Aerobic High Intensity Training (HIT)
Study: NCT03561584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Patients will be initiated on a low dose of sulfasalazine (500 mg) twice daily (bid). Dosage will be increased throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be initiated on 1 placebo tablet twice daily (bid). Dosage will be increased throughout the study.
Study: NCT02324270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac epolamine
Description: Diclofenac epolamine in a topical patch formulation; applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine
Description: Diclofenac epolamine in a topical patch formulation; applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical patch not containing diclofenac epolamine applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
Study: NCT03858959

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: topical agent
Description: HBX protocol consisted in product application into the periodontal pocket (starting from the base) with a delivery syringe, second saline solution irrigation after 60 seconds to flush-out the product and Teflon-curettes debridement to remove the deposits.~CHX protocol consisted in Teflon-curettes debridement to remove the deposits, associated with a first saline solution irrigation, and product application into the periodontal pocket (starting from the base) with a delivery syringe.
Study: NCT02482038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko
Description: neuromuscular electrostimulator
Study: NCT02586441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Raw EEG signals were acquired at a sampling rate of 128Hz using a BIS-VISTATM monitor and was measured during all anesthetic period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: intravenous 1% propofol (1.5-2.5 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: intravenous rocuronium bromide (0.6 mg/kg)
Study: NCT03303664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMPROVE Protocol
Description: Comprehensive pain management protocol
Study: NCT02192333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of Therapy Complications
Description: Receive survivorship care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive phone-based booster intervention
Study: NCT01057641

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spacer
Description: Implantation of a percutaneously implanted interspinous device (spacer)

Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapy
Description: physiotherapy
Study: NCT00945295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A, BoNT-A
Description: Participants will receive IM injections of BoNT-A between 200 and 400 Units with the total dose not to exceed 6 U / kg. The primary targets for BoNT-A injection are the wrist and finger flexor muscles (flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, flexor digitorum superficialis).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A, BoNT-A
Description: Participants will receive IM injections of BoNT-A between 200 and 400 Units with the total dose not to exceed 6 U / kg. The primary targets for BoNT-A injection are the wrist and finger flexor muscles (flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, flexor digitorum superficialis).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation Therapy
Description: Rehabilitation therapy
Study: NCT00335179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldara (imiquimod 5% cream)
Description: Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream in 250 mg
Study: NCT03133884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 30 seconds.

Intervention type: OTHER
Group type: OTHER
Intervention: superficial acupuncture
Description: The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
Study: NCT03300102

Intervention type: OTHER
Intervention: Questionnaires, interviews and or tissue donation
Description: Subjects will be asked to complete either structured questionnaires, semi-structured interviews or donate tissue. There will be some overlap, but each subject does not have to do all three interventions.
Study: NCT04408378

Intervention type: OTHER
Intervention: observation of covid 19 pneumonia
Description: We try to reveal the fact,covid-19 pneumonia prognosis can be estimated by using MPV/PLT ratio

Intervention type: OTHER
Intervention: observation of covid 19 pneumonia
Description: We try to reveal the fact,covid-19 pneumonia prognosis can be estimated by using MPV/PLT ratio
Study: NCT03858959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: topical agent
Description: HBX protocol consisted in product application into the periodontal pocket (starting from the base) with a delivery syringe, second saline solution irrigation after 60 seconds to flush-out the product and Teflon-curettes debridement to remove the deposits.~CHX protocol consisted in Teflon-curettes debridement to remove the deposits, associated with a first saline solution irrigation, and product application into the periodontal pocket (starting from the base) with a delivery syringe.
Study: NCT01952587

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: A peripheral blood sample
Description: A peripheral blood sample will be collected from HIV-infected subjects and healthy control to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
Study: NCT04408378

Intervention type: OTHER
Intervention: observation of covid 19 pneumonia
Description: We try to reveal the fact,covid-19 pneumonia prognosis can be estimated by using MPV/PLT ratio
Study: NCT02812498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: The patients in the consultation group arranged their bookings on a website, where they could also access to web educational courses or to nutritional and psychological counselling

Intervention type: OTHER
Group type: OTHER
Intervention: Standard
Description: Group of patients followed in a traditional way
Study: NCT02249897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOLESTYRAMINE
Description: CHOLESTYRAMINE CAPSULES, 6 G/DAY P.O. DURING 12 WEEKS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CHOLESTYRAMINE
Description: CHOLESTYRAMINE CAPSULES, 6 G/DAY P.O. DURING 12 WEEKS
Study: NCT03472846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia, 60 Mg/mL Subcutaneous Solution
Description: antiresorptive treatment with Prolia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia, 60 Mg/mL Subcutaneous Solution
Description: antiresorptive treatment with Prolia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: osteoanabolic treatment with Forsteo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: osteoanabolic treatment with Forsteo
Study: NCT01078818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV trivalent saccharose hydroxide ferrous
Description: Preoperative Period 5-10 days 200 mg Iron iv (Venofer® )in 200cc physiologic solution /24-48h x 3 dosis +1 oral placebo /24h Postoperative Period 1-3weeks 200 mg Iron iv (Venofer® )in 200cc physiologic solution/24-48h x 3 dosis + 1 oral placebo /24h One month Follow-up~1 month 1 oral placebo /24h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ferrous fumarate
Description: 200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®)~Postoperative Period:~200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®) One month Follow-up: 1 oral iron tablet/24h Ferogradumet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral and intravenous Placebo
Description: Preoperative Period:1oral placebo/24h Postoperative Period:200cc physiologic solution iv placebo /24-48h x 3 dosis + 1oral placebo/24h One month Follow-up:1 oral placebo/24h
Study: NCT03506230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: A bonus to buy their medications if they reduce their HBA1c
Study: NCT05160142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DICE
Description: 10-week culinary and nutrition education program for children with type I diabetes
Study: NCT00875693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio.
Study: NCT01412489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYALOBARRIER Gel
Description: For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
Study: NCT01208753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0555
Description: two different aqueous formulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0555 aqueous
Description: multiple dose, aqueous formulation, 13 days, 100 mg/day once daily, maximum dose to be determined

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
Study: NCT00579384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26489112
Description: Single oral dose of JNJ-26489112 up to 3000 mg on Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo on Day 1, and a second single dose of placebo on Day 3.